ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
ANI Pharma (ANIP) Tops Q1 EPS by 15c; Suspends FY20 Guidance
May 7, 2020 8:35 AM EDTANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.04, $0.15 better than the analyst estimate of $0.89. Revenue for the quarter came in at $49.8 million versus the consensus estimate of $50.23 million.
For the first quarter 2020, ANI reports:
Net revenues of $49.8 million versus $52.9 million in 2019GAAP net loss of $7.0 million and diluted GAAP loss per share of $0.59Adjusted non-GAAP EBITDA of $17.6 millionAdjusted non-GAAP diluted earnings per share of $1.04Arthur S. Przybyl, President and CEO,... More
